TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03611465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pace-mapping
Description: Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pace-mapping
Description: Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard pace-mapping examination
Description: Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
Study: NCT00555789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic plus tacrolimus
Description: 720mg b.i.d. 2yrs
Study: NCT02764190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT with Check Yourself
Study: NCT01233687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 and erlotinib
Description: Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102.
Study: NCT00089674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Study: NCT02914145

Intervention type: DRUG
Group type: OTHER
Intervention: Dihydroartemisinin-piperaquine
Description: Mass drug administration
Study: NCT03420053

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: 0.9% sodium chloride solution
Study: NCT00652639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Tablets, 1 mg, single-dose
Study: NCT03420053

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
Study: NCT00652639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klonopin
Description: tablets, 1 mg, single-dose
Study: NCT03095768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Education and Cooking Demonstration
Description: Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
Study: NCT00876603

Intervention type: PROCEDURE
Intervention: ACDF
Description: Anterior cervical decompression and fusion

Intervention type: PROCEDURE
Intervention: Cervical laminoplasty
Description: Cervical laminoplasty
Study: NCT03420053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
Study: NCT01706094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head Position
Description: Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients.
Study: NCT00617396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg/day-100mg/day)
Description: Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
Study: NCT05146076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based physical training
Description: home-based physical training minimum 150 min./week with telemonitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: institutional physical training
Description: institutional physical training supervised by physiotherapist 2-3 times 60 min./week
Study: NCT00606281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 0mg(4tablets)/day
Study: NCT01710774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine follow-up care
Description: Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
Study: NCT03386760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Utilisation PicoSecond
Description: Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Utilisation Nano-second
Description: Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions
Study: NCT01000376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin alone
Description: Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m\^2 alone on Day 1, then eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin plus Ketoconazole
Description: Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m\^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
Study: NCT05081375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Injectable Product
Description: Not holding prophylaxis dose prior to surgical procedure
Study: NCT01851304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of breads
Description: One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of breads
Description: One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
Study: NCT05081375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Holding prophylaxis dose of Enoxaparin replacing with placebo
Study: NCT03557489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum
Description: Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
Study: NCT01851304

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Satiety of breads
Description: One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of breads
Description: One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Satiety of puddings
Description: One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of puddings
Description: One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of puddings
Description: One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
Study: NCT03607136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
Study: NCT03691870

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Trans-Arterial Embolization (TAE)
Description: The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Venous Embolization (TVE)
Description: The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion.
Study: NCT02347956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced port robotic distal gastrectomy
Study: NCT01129284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR gel
Description: Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
Study: NCT00894725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic left colonic resection
Description: laparoscopic colonic resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left colonic resection
Description: conventional open colonic resection
Study: NCT03974490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation
Description: Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
Study: NCT01992471

Intervention type: BEHAVIORAL
Intervention: Pre-test Assessment
Description: Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
Study: NCT02918981

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 14 g Whey protein
Study: NCT01992471

Intervention type: BEHAVIORAL
Intervention: Pre test Counseling
Description: Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
Study: NCT00834444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famvir® 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting
Study: NCT00549822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
Study: NCT03319108

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Pulmonary Rehabilitation Program for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Pulmonary Rehabilitation Program for 8 weeks
Study: NCT04365387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab will be administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
Study: NCT02254005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study: NCT04353362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: 400 mg, 1 time per day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 500 mg, 3 times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg, 3 times per day, for 7 days
Study: NCT01747668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Prenatal Vitamin soft-gel capsule
Description: One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Prenatal Vitamin soft-gel capsule
Description: One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (soybean oil and dl-alpha-tocopheryl acetate)
Description: Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (soybean oil and dl-alpha-tocopheryl acetate)
Description: Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
Study: NCT04168398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Anticoagulation
Study: NCT02222064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
Study: NCT00747305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study: NCT01992471

Intervention type: OTHER
Intervention: Blood draw
Description: After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.

Intervention type: BEHAVIORAL
Intervention: Post-test counseling, and post-test assessment
Description: When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
Study: NCT00747305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01992471

Intervention type: BEHAVIORAL
Intervention: Follow-up assessments (6 and 12 months)
Description: At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
Study: NCT00422461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral, tablets, once daily, for 28 days
Study: NCT00747305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT03220958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 100ml normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100ml normal saline
Study: NCT02742194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry extract of ginger
Description: Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
Study: NCT02584907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Enteral Nutrition
Description: Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
Study: NCT00422461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 4 mg, oral, tablets, once daily, for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 10 mg, oral, tablets, once daily, for 28 days
Study: NCT04633304

Intervention type: DEVICE
Group type: OTHER
Intervention: EndoAVF System for endovascular AV fistula creation
Description: AV fistula creation
Study: NCT04242602

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler
Description: Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
Study: NCT00908388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE TAG® Thoracic Endoprosthesis
Description: Endoprosthetic Implant
Study: NCT00832962

Intervention type: GENETIC
Intervention: Genotyping
Description: Whole blood sample

Intervention type: OTHER
Intervention: Usual prophylaxis
Description: Prophylactic anti-RhD